This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Arcellx (ACLX) Stock Overview

Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. More details

ACLX fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 75.9% below our estimate of its fair value

Earnings are forecast to grow 63.73% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Significant insider selling over the past 3 months

ACLX Community Fair Values

Create Narrative

See what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW437,855 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

437,855 investors already sharing narratives

View all narratives

Arcellx, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Arcellx
Historical stock prices
Current Share Price	US$115.07
52 Week High	US$115.13
52 Week Low	US$47.86
Beta	0.25
1 Month Change	0.22%
3 Month Change	68.45%
1 Year Change	75.60%
3 Year Change	166.00%
5 Year Change	n/a
Change since IPO	584.94%

Recent updates

Seeking Alpha • Dec 17

Arcellx: Funded Into 2028 With Strong Clinical Data

Summary Arcellx (ACLX) is positioned to disrupt multiple myeloma cell therapy with anito-cel, leveraging superior efficacy, safety, and scalable manufacturing. ACLX's $576 million cash runway extends into 2028, mitigating dilution risk and supporting its transition to commercialization post-2026 launch. Anito-cel's 96% ORR, 74% CR/sCR, and clean safety profile differentiate it from competitors, especially against Carvykti’s neurotoxicity concerns. The Kite partnership ensures rapid 17-day turnaround and broad distribution, enhancing ACLX's commercial leverage in a $12B+ market. Read the full article on Seeking Alpha

Seeking Alpha • Mar 17

Arcellx Impressive Safety Data Leaves Doubts

Summary Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet medical need. Strong clinical trial results and strategic partnerships bolster confidence in Arcellx's growth trajectory and market position. Clarity is needed around mechanistic differentiation on D-Domain safety results before fully buying into the story. Hold rating based on the uncertainty of upcoming potential approval. Read the full article on Seeking Alpha

Seeking Alpha • Jan 16

Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy

Summary Arcellx's anito-cel shows promising efficacy and safety in multiple myeloma, with a 97% response rate and low neurotoxicity, potentially differentiating it in a crowded market. Financially robust, ACLX has cash reserves to fund operations into 2027, supported by a collaboration with Gilead's Kite subsidiary. Despite the promising data, the myeloma treatment landscape is competitive, and ACLX must overcome significant hurdles in cost, manufacturing, and delivery. Given the current $3.5 billion market cap, I maintain a "Hold" sentiment, anticipating a pullback for a more favorable entry point, although your risk tolerance may vary. Read the full article on Seeking Alpha

Seeking Alpha • Sep 10

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Summary Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows strong clinical results in relapsed/refractory multiple myeloma, even for high-risk patients. Arcellx’s strategic partnership with Kite Pharma validates its technology, potentially leading to milestone payments of up to $935 million. Anito-cel’s Phase 3 trial results are expected by yearend 2024, with a possible BLA submission in 2025, entering a $34.4 billion market. Despite a premium valuation, ACLX's strong pipeline, promising clinical data and strategic partnership with Gilead's Kite justify a "strong-buy" rating. Read the full article on Seeking Alpha

Shareholder Returns

	ACLX	US Biotechs	US Market
7D	0.02%	-5.9%	-2.2%
1Y	75.6%	34.6%	13.1%

Return vs Industry: ACLX exceeded the US Biotechs industry which returned 27.9% over the past year.

Return vs Market: ACLX exceeded the US Market which returned 27.6% over the past year.

Price Volatility

Is ACLX's price volatile compared to industry and market?
ACLX volatility
ACLX Average Weekly Movement	22.7%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.9%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.9%

Stable Share Price: ACLX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ACLX's weekly volatility has increased from 13% to 23% over the past year.

About the Company

Founded	Employees	CEO	Website
2014	209	Rami Elghandour	www.arcellx.com

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Arcellx, Inc. Fundamentals Summary

How do Arcellx's earnings and revenue compare to its market cap?
ACLX fundamental statistics
Market cap	US$6.75b
Earnings (TTM)	-US$228.93m
Revenue (TTM)	US$22.29m

302.9x

P/S Ratio

-29.5x

P/E Ratio

Is ACLX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACLX income statement (TTM)
Revenue	US$22.29m
Cost of Revenue	US$157.61m
Gross Profit	-US$135.32m
Other Expenses	US$93.61m
Earnings	-US$228.93m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-3.90
Gross Margin	-607.22%
Net Profit Margin	-1,027.25%
Debt/Equity Ratio	0%

How did ACLX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/30 13:17
End of Day Share Price	2026/04/27 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arcellx, Inc. is covered by 6 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jason Matthew Gerberry	BofA Global Research
Geoffrey Meacham	Citigroup Inc
Cory Kasimov	Evercore ISI

This company has been acquired

Arcellx (ACLX) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Arcellx, Inc. Competitors

Halozyme Therapeutics

Alkermes

Cogent Biosciences

Celcuity

Price History & Performance

Recent News & Updates

Arcellx, Inc.(NasdaqGM:ACLX) dropped from NASDAQ Composite Index

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of 77.2% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others.

Arcellx, Inc.(NasdaqGS:ACLX) dropped from Russell 2000 Growth Index

Chairman of the Board recently sold US$10m worth of stock

Full year 2025 earnings: EPS in line with expectations, revenues disappoint

Chief Financial Officer notifies of intention to sell stock

Recent updates

Arcellx, Inc.(NasdaqGM:ACLX) dropped from NASDAQ Composite Index

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of 77.2% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others.

Arcellx, Inc.(NasdaqGS:ACLX) dropped from Russell 2000 Growth Index

Chairman of the Board recently sold US$10m worth of stock

Full year 2025 earnings: EPS in line with expectations, revenues disappoint

Chief Financial Officer notifies of intention to sell stock

New major risk - Share price stability

Chief Financial Officer recently sold US$785k worth of stock

Chief Financial Officer notifies of intention to sell stock

Arcellx, Inc. Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder

Independent Director notifies of intention to sell stock

Chief Medical Officer recently sold US$487k worth of stock

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates decrease by 13%

Forecast to breakeven in 2028

Arcellx: Funded Into 2028 With Strong Clinical Data

Arcellx, Inc. Announces New Positive Data from Its Pivotal Phase 2 iMMagine-1 Study of Anitocabtage Neautoleucel in Patients with Relapsed or Refractory Multiple Myeloma

Consensus revenue estimates fall by 33%

Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcellx to Present New Data for its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Chief Financial Officer notifies of intention to sell stock

Arcellx, Inc. Announces New Positive Data for Its Immagine-1 Study in Patients with Relapsed And/Or Refractory Multiple Myeloma

Consensus EPS estimates fall by 37%

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Arcellx, Inc., Annual General Meeting, May 28, 2025

Arcellx Impressive Safety Data Leaves Doubts

Consensus EPS estimates fall by 29%

Consensus revenue estimates fall by 27%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Chairman of the Board recently sold US$2.4m worth of stock

Chief Medical Officer notifies of intention to sell stock

Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy

Chairman of the Board notifies of intention to sell stock

Insufficient new directors

Consensus EPS estimates fall by 11%

Chief Financial Officer notifies of intention to sell stock

Price target increased by 9.7% to US$105

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Independent Director notifies of intention to sell stock

Price target increased by 7.1% to US$89.67

Now 20% overvalued after recent price rise

Chief Financial Officer notifies of intention to sell stock

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$320k worth of stock

Consensus revenue estimates increase by 21%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 21% undervalued after recent price drop

Chief Medical Officer exercised options and sold US$990k worth of stock

Now 21% overvalued after recent price rise

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 14%

Chief Financial Officer notifies of intention to sell stock